NanoViricides, Inc., Moves to OTC Bulletin Board

NanoViricides, Inc. (the "Company") announced today that it has completed its transition onto NASD's OTC Bulletin Board, with approval for listing under the symbol "NNVC.OB".

The move culminates work that began in March when the Company's Form 10-SB became effective with the Securities and Exchange Commission and the Company became fully reporting.

"This is an exciting time for NanoViricides," said CEO Eugene Seymour MD. "Just as our work is gaining increasing recognition within the scientific community, this transition and new listing demonstrates the integrity of our business strategy to the investment community as well," continued Seymour.

Acceptance on the Bulletin Board formalizes commitment to full corporate transparency and accountability to its shareholders, said Seymour.

Interested investors may contact us at:   investors@nanoviricides.com

About NanoViricides, Inc.

NanoViricides, Inc. is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide ™ class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H5N1 bird flu, seasonal influenza, rabies, dengue fever, HIV, hepatitis C, among others.

This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors.

Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward looking statements are subject to known and unknown risks, uncertainties and other factors including the availability of adequate financing, the success of the Company's research and development strategy, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process, described in the "Management's Discussion and Analysis" section of the Company's Form 10-KSB and other reports and filings with the Securities and Exchange Commission. Such risks, uncertainties and other factors may cause actual results, performance, or achievements of the Company to be different from those expressed or implied by the Company.

SEC 10-SB submission